Insider · CIK 0001543084

van Deventer Sander

Reports to the SEC for 3 companies · 1411 DC NAARDEN, P7

sec.gov

Transactions

Companies

Filings

CIK

0001543084

Forms 4 and 5

Insider transactions

38 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2020-10-21	HOOKHOOKIPA Pharma Inc.A Award	Director	AAward	+2,485 sh	—	—	2,485
2020-06-18	HOOKHOOKIPA Pharma Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+9,600 sh	—	—	9,600
2020-02-27	QUREuniQure N.V.A Award	EVP, Research & Product Dev.	AAward	+12.4K sh	—	—	61,599
2020-02-27	QUREuniQure N.V. · Stock Option (Right to Buy)A Award	EVP, Research & Product Dev.	AAward	+21.7K sh	—	—	21,719
2020-01-31	QUREuniQure N.V.A Award	EVP, Research & Product Dev.	AAward	+6,092 sh	—	—	49,219
2020-01-28	QUREuniQure N.V.S Sale	EVP, Research & Product Dev.	SSale	−1,304 sh	$61.27	−$79.9K	44,050
2020-01-28	QUREuniQure N.V.S Sale	EVP, Research & Product Dev.	SSale	−923 sh	$62.10	−$57.3K	43,127
2019-12-18	HOOKHOOKIPA Pharma Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+9,600 sh	—	—	9,600
2019-09-17	QUREuniQure N.V.A Award	EVP, Research & Product Dev.	AAward	+15K sh	—	—	45,354
2019-04-17	HOOKHOOKIPA Pharma Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+19.2K sh	—	—	19,200
2019-01-28	QUREuniQure N.V.S Sale	EVP, Research & Product Dev.	SSale	−1,358 sh	$31.31	−$42.5K	40,313
2019-01-25	QUREuniQure N.V.A Award	EVP, Research & Product Dev.	AAward	+5,589 sh	—	—	30,658
2019-01-25	QUREuniQure N.V.A Award	EVP, Research & Product Dev.	AAward	+10.9K sh	—	—	41,571
2019-01-25	QUREuniQure N.V. · Stock Option (Right to Buy)A Award	EVP, Research & Product Dev.	AAward	+18.3K sh	—	—	18,325
2018-01-29	QUREuniQure N.V.S Sale	EVP, Research & Product Dev.	SSale	−5,985 sh	$18.53	−$111K	25,069
2018-01-26	QUREuniQure N.V.A Award	EVP, Research & Product Dev.	AAward	+7,795 sh	—	—	31,054
2018-01-26	QUREuniQure N.V. · Stock Option (Right to Buy)A Award	EVP, Research & Product Dev.	AAward	+20.8K sh	—	—	20,788
2017-09-20	QUREuniQure N.V. · Stock Option (Right to Buy)A Award	EVP, Research & Product Dev.	AAward	+150K sh	—	—	150,000
2017-01-27	QUREuniQure N.V. · Stock Option (Right to Buy)A Award	EVP, Research & Product Dev.	AAward	+11K sh	—	—	11,000
2017-01-27	QUREuniQure N.V. · Restricted Stock UnitsA Award	EVP, Research & Product Dev.	AAward	+11K sh	—	—	16,000
2017-01-19	ARGOS THERAPEUTICS INCStock Option (right to buy)A Award	Director	AAward	+9,500 sh	—	—	9,500
2016-09-30	ARGOS THERAPEUTICS INCA Award	Director	AAward	+2,263 sh	—	—	5,057
2016-08-02	ARGOS THERAPEUTICS INCP Purchase	Director	PPurchase	+1.55M sh	—	—	6,199,961
2016-08-02	ARGOS THERAPEUTICS INCCommon Stock Warrants (right to buy)P Purchase	Director	PPurchase	+1.16M sh	—	—	1,159,090
2016-06-30	ARGOS THERAPEUTICS INCA Award	Director	AAward	+1,427 sh	—	—	2,794
2016-06-29	ARGOS THERAPEUTICS INCP Purchase	Director	PPurchase	+1.32M sh	—	—	4,654,507
2016-06-29	ARGOS THERAPEUTICS INCCommon Stock Warrants (right to buy)P Purchase	Director	PPurchase	+992K sh	—	—	991,964
2016-06-13	ARGOS THERAPEUTICS INCStock Option (right to buy)A Award	Director	AAward	+5,500 sh	—	—	5,500
2016-03-31	ARGOS THERAPEUTICS INCA Award	Director	AAward	+1,367 sh	—	—	1,367
2016-03-14	ARGOS THERAPEUTICS INCP Purchase	Director	PPurchase	+882K sh	—	—	3,331,889
2016-03-14	ARGOS THERAPEUTICS INCCommon Stock Warrants (right to buy)P Purchase	Director	PPurchase	+661K sh	—	—	661,309
2015-06-17	ARGOS THERAPEUTICS INCStock Option (right to buy)A Award	Director	AAward	+5,500 sh	—	—	5,500
2014-03-20	ARGOS THERAPEUTICS INCStock Option (right to buy)A Award	Director	AAward	−11K sh	—	—	11,000
2014-02-12	ARGOS THERAPEUTICS INCC Conversion	Director	CConversion	+985K sh	—	—	984,840
2014-02-12	ARGOS THERAPEUTICS INCC Conversion	Director	CConversion	+1.43M sh	—	—	2,413,728
2014-02-12	ARGOS THERAPEUTICS INCP Purchase	Director	PPurchase	+36.4K sh	$8.00	+$291K	2,450,144
2014-02-12	ARGOS THERAPEUTICS INCSeries D Preferred StockC Conversion	Director	CConversion	−985K sh	—	—	0
2014-02-12	ARGOS THERAPEUTICS INCSeries E Preferred StockC Conversion	Director	CConversion	−1.43M sh	—	—	0

Recent filings

Accepted (ET)
Oct 234
van Deventer Sander0001104659-20-117709
SEC(opens sec.gov)
Jun 194
van Deventer Sander0001104659-20-075260
SEC(opens sec.gov)
Mar 24
van Deventer Sander0000904454-20-000251
SEC(opens sec.gov)
Jan 314
van Deventer Sander0000904454-20-000132
SEC(opens sec.gov)
Jan 304
van Deventer Sander0000904454-20-000114
SEC(opens sec.gov)
Jan 34
van Deventer Sander0001104659-20-000850
SEC(opens sec.gov)
Sep 194
van Deventer Sander0000904454-19-000642
SEC(opens sec.gov)
Apr 244
van Deventer Sander0001104659-19-023443
SEC(opens sec.gov)
Jan 304
van Deventer Sander0000904454-19-000126
SEC(opens sec.gov)
Jan 294
van Deventer Sander0000904454-19-000115
SEC(opens sec.gov)
Jan 314
van Deventer Sander0000904454-18-000093
SEC(opens sec.gov)
Jan 304
van Deventer Sander0000904454-18-000084
SEC(opens sec.gov)
Sep 224
van Deventer Sander0001209191-17-053713
SEC(opens sec.gov)
Jan 314
uniQure N.V.0001140361-17-003707
SEC(opens sec.gov)

Companies

Address

C/O FORBION CAPITAL PARTNERS GOOIMEER 2-35

1411 DC NAARDEN, P7